Nonspecific HUD Plays A Critical Role in Chromatin Regulation and DNA Replication

Target Name: Histone Lysine Demethylase

NCBI ID: P18378

Histone Lysine Demethylase

Other Name(s): None

Nonspecific HUD Plays A Critical Role in Chromatin Regulation and DNA Replication

Histone lysine demethylase (HUD) is a protein that plays a critical role in chromatin regulation and DNA replication. Mutations in HUD genes have been linked to various genetic disorders, including cancer, neurodegenerative diseases, and developmental disorders. The nonspecific subtype of HUD, also known as HDAC1 or HDAC-like, is a subclass of histone lysine demethylase that has unique functions and is of interest as a drug target or biomarker.

HUD is a histone-modifying enzyme that removes a methyl group from the lysine residue on histone proteins. This process is essential for the regulation of gene expression and DNA replication. During DNA replication, the double helix is duplicated, and the addition of methyl groups to the lysine residues on the histones can prevent the addition of nucleotides, leading to errors in replication. HUD removes these methyl groups, allowing for accurate replication and gene expression.

The nonspecific subtype of HUD is unique in that it has a different catalytic mechanism than other histone lysine demethylases. Unlike other HDACs, which use a Michaelis-Menten mechanism, HUD uses a ratchet mechanism. This mechanism is more efficient and allows for faster demethylation of multiple lysine residues in a single reaction.

HUD has also been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation. For example, HUD has been shown to be involved in the regulation of cell cycle progression and the establishment of cell pluripotency. Additionally, HUD has been linked to the regulation of cellular immune responses, where it has been shown to play a role in the regulation of T cell development and function.

As a result of its unique functions and its involvement in various cellular processes, HUD has been identified as a potential drug target or biomarker. Studies have shown that inhibiting HUD has been shown to have therapeutic effects in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, HUD has been shown to be involved in the regulation of cancer cell growth and has been used as a potential therapeutic target in cancer treatment. Additionally, HUD has been linked to the development of neurodegenerative diseases, including Alzheimer's disease, and has been shown to play a role in the regulation of neurotransmitter synthesis and release.

In conclusion, the nonspecific subtype of histone lysine demethylase (HUD) is a protein that plays a critical role in chromatin regulation and DNA replication. It is unique in its use of the ratchet mechanism for demethylation and its involvement in various cellular processes. As a result of its functions, HUD has been identified as a potential drug target or biomarker, with studies showing that inhibiting HUD has therapeutic effects in various diseases. Further research is needed to fully understand the functions of HUD and its potential as a drug or biomarker.

Protein Name: Histone Lysine Demethylase (nonspecified Subtype)

The "Histone Lysine Demethylase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Histone Lysine Demethylase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets